Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Fulgent Genetics

Fulgent Genetics (NASDAQ: FLGT) insider transactions

In the twelve months to 10 November 2026, executives and directors of Fulgent Genetics reported 15 open-market sales of 27,484 shares ($677,628) and 0 open-market purchases, by 2 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Fulgent Genetics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
26 October 2026Kim PaulCFO and TreasurerShares withheld for tax−2,748$20.22353,795Form 4
26 October 2026Xie JianPresident and COOShares withheld for tax−4,361$20.22355,563Form 4
26 October 2026Gao HanlinChief Scientific OfficerShares withheld for tax−1,645$20.22984,472Form 4
2 September 2026Gao HanlinChief Scientific OfficerOpen-market sale−1,673$19.66986,117Form 4
2 September 2026Xie JianPresident and COOOpen-market sale−2,127$19.66359,924Form 4
1 September 2026Kim PaulCFO and TreasurerShares withheld for tax−2,087$19.59356,543Form 4
1 September 2026Hsieh MingChief Executive OfficerShares withheld for tax−4,392$19.59885,952Form 4
27 August 2026Gao HanlinChief Scientific OfficerOpen-market sale−939$19.91987,790Form 4
27 August 2026Xie JianPresident and COOOpen-market sale−1,193$19.91362,051Form 4
26 August 2026Kim PaulCFO and TreasurerShares withheld for tax−1,168$19.81358,630Form 4
26 August 2026Hsieh MingChief Executive OfficerShares withheld for tax−2,949$19.81890,344Form 4
26 July 2026Gao HanlinChief Scientific OfficerShares withheld for tax−1,645$19.67988,729Form 4
26 July 2026Xie JianPresident and COOShares withheld for tax−4,361$19.67363,244Form 4
26 July 2026Kim PaulCFO and TreasurerShares withheld for tax−2,747$19.67359,798Form 4
2 June 2026Gao HanlinChief Scientific OfficerOpen-market sale−1,688$17.89990,374Form 4
2 June 2026Xie JianPresident and COOOpen-market sale−2,146$17.89367,605Form 4
1 June 2026Kim PaulCFO and TreasurerShares withheld for tax−2,087$18.09362,545Form 4
1 June 2026Hsieh MingChief Executive OfficerShares withheld for tax−4,392$18.09893,293Form 4
27 May 2026Gao HanlinChief Scientific OfficerOpen-market sale−945$17.60992,062Form 4
27 May 2026Xie JianPresident and COOOpen-market sale−1,201$17.60369,751Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Fulgent Genetics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.